Metforal

Active Ingredient:: Metformin Hydrochloride
Origin:: EU

Metforal (Metformin Hydrochloride)

Q: What is Metforal used for?

Metforal contains metformin hydrochloride and is prescribed to lower blood glucose in adults with type 2 diabetes mellitus. It is also used to improve glycaemic control in patients with prediabetes and, in some clinical settings, to manage insulin resistance associated with polycystic ovary syndrome.

Q: How does Metformin Hydrochloride work?

Metformin Hydrochloride reduces hepatic glucose production by inhibiting mitochondrial complex I, which lowers gluconeogenesis. It also enhances peripheral insulin sensitivity, promoting glucose uptake in muscle and adipose tissue, thereby helping to control blood sugar levels without stimulating insulin secretion.

Q: What is the usual dose of Metforal?

The appropriate dose of Metforal is determined by the prescribing healthcare professional based on the individual’s renal function, glycaemic targets, and tolerability. Dosage may be started low and titrated upward, but exact amounts should only be set by a qualified prescriber.

Q: Is Metforal safe during pregnancy or breastfeeding?

The pregnancy safety category for Metforal is not definitively established. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their physician, who can decide whether continuation is appropriate.

Q: How do I order Metforal from GNH India?

To order Metforal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Q: How does Metforal compare with other antidiabetic drugs?

Metforal belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. Unlike secretagogues, metformin does not increase insulin secretion, reducing hypoglycaemia risk. It is often used as first‑line therapy because of its efficacy, weight‑neutral profile, and cardiovascular benefits, whereas other classes may have different mechanisms and side‑effect profiles.

Q: How should Metforal be stored and handled?

Metforal should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Q: How is Metforal administered?

Metforal is taken orally, usually with meals to minimise gastrointestinal discomfort. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Q: What are the most serious risks to watch for while taking Metforal?

The most serious adverse reaction associated with Metforal is lactic acidosis, a rare but life‑threatening condition characterized by rapid breathing, muscle pain, and abdominal discomfort. Signs of severe hypoglycaemia, especially when combined with insulin or sulfonylureas, also require immediate medical attention.

Q: Who should not use Metforal?

Metforal is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and those who have experienced lactic acidosis while on metformin. Caution is also advised for individuals with significant liver disease or heart failure.

Metformin Hydrochloride, the active ingredient in Metforal, is a biguanide presented as an oral tablet for oral use. It lowers hepatic glucose production and improves peripheral insulin sensitivity, making it a cornerstone therapy for adults with type 2 diabetes mellitus and for certain patients with impaired glucose tolerance.

GNH India supplies Metforal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratori Guidotti S.P.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metforal (metformin hydrochloride) is used in the management of disorders related to glucose metabolism.

Type 2 diabetes mellitus: improves glycemic control by reducing fasting and post‑prandial glucose levels.
Prediabetes (impaired glucose tolerance): delays progression to overt diabetes when combined with lifestyle measures.
Polycystic ovary syndrome (PCOS): helps restore ovulatory cycles and reduce insulin resistance in women.

How It Works

Metformin acts primarily by inhibiting mitochondrial respiratory‑chain complex I, which reduces hepatic gluconeogenesis. The resulting decrease in hepatic glucose output, together with enhanced insulin‑mediated glucose uptake in muscle and adipose tissue, improves overall insulin sensitivity. It does not stimulate insulin secretion, thereby lowering the risk of hypoglycaemia when used as monotherapy.

Side Effects

Metforal may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea.
Metallic taste: transient alteration of taste perception.
Weight loss: modest reduction in body weight.

Serious or Rare Side Effects

Lactic acidosis: a rare but potentially fatal accumulation of lactate.
Severe hypoglycaemia: usually when combined with insulin or sulfonylureas.
Hepatotoxicity: abnormal liver enzymes indicating liver injury.
Vitamin B12 deficiency: long‑term use may reduce absorption.

Precautions & Warnings

When prescribing Metforal, clinicians should consider several safety precautions.

Renal function assessment: evaluate eGFR before initiation and periodically thereafter.
Contraindication in severe renal impairment: avoid use if eGFR <30 mL/min/1.73 m².
Monitor for lactic acidosis: watch for unexplained acidosis, especially after surgery or in hypoxic states.
Use with caution in hepatic disease: assess liver function because impaired clearance can increase risk.
Adjust dose in elderly patients: start at lower dose and titrate slowly.
Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Avoid Interactions

Metforal can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

Iodinated contrast agents: may precipitate acute renal failure; discontinue metformin before and after imaging.
Cimetidine: increases metformin plasma concentrations, raising risk of lactic acidosis.
Alcohol excess: potentiates lactic acidosis risk.

Moderate Interactions (Monitor Closely)

Sulfonylureas or insulin: combined therapy can increase hypoglycaemia risk.
Diuretics (e.g., thiazides): may affect renal clearance of metformin.
Corticosteroids: can raise blood glucose, reducing metformin effectiveness.
ACE inhibitors or ARBs: monitor renal function as combined effect may affect kidney.

Frequently Asked Questions

Metforal contains metformin hydrochloride and is prescribed to lower blood glucose in adults with type 2 diabetes mellitus. It is also used to improve glycaemic control in patients with prediabetes and, in some clinical settings, to manage insulin resistance associated with polycystic ovary syndrome.

Metformin Hydrochloride reduces hepatic glucose production by inhibiting mitochondrial complex I, which lowers gluconeogenesis. It also enhances peripheral insulin sensitivity, promoting glucose uptake in muscle and adipose tissue, thereby helping to control blood sugar levels without stimulating insulin secretion.

The appropriate dose of Metforal is determined by the prescribing healthcare professional based on the individual’s renal function, glycaemic targets, and tolerability. Dosage may be started low and titrated upward, but exact amounts should only be set by a qualified prescriber.

The pregnancy safety category for Metforal is not definitively established. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their physician, who can decide whether continuation is appropriate.

To order Metforal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metforal belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. Unlike secretagogues, metformin does not increase insulin secretion, reducing hypoglycaemia risk. It is often used as first‑line therapy because of its efficacy, weight‑neutral profile, and cardiovascular benefits, whereas other classes may have different mechanisms and side‑effect profiles.

Metforal should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Metforal is taken orally, usually with meals to minimise gastrointestinal discomfort. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse reaction associated with Metforal is lactic acidosis, a rare but life‑threatening condition characterized by rapid breathing, muscle pain, and abdominal discomfort. Signs of severe hypoglycaemia, especially when combined with insulin or sulfonylureas, also require immediate medical attention.

Metforal is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and those who have experienced lactic acidosis while on metformin. Caution is also advised for individuals with significant liver disease or heart failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 05 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.